Claims for Patent: 10,065,995

Summary for Patent: 10,065,995

Title:	Protein for affinity-separation matrix
Abstract:	An object of the present invention is to provide a technique to create novel engineered protein ligands that, when immobilized through a lysine residue (its side chain ε-amino group) which allows for efficient immobilization to a carrier, show the optimum binding capacity and binding efficiency to a target molecule. The present invention provides an engineered protein having a sequence obtained by replacing all the lysine residues in Protein A, which is the most typical protein ligand, with other amino acids, and adding lysine at a terminal; and an affinity separation matrix in which such an engineered protein is immobilized on a water-insoluble carrier by reductive amination or the like. This affinity separation matrix is characterized by its high binding capacity to a target molecule even when the immobilized amount of the ligand is small.
Inventor(s):	Shinichi Yoshida, Dai Murata, Shunichi Taira
Assignee:	Kaneka Corp
Application Number:	US14/007,225

Details for Patent 10,065,995

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	July 13, 2017	10,065,995	2032-03-26
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	January 29, 2019	10,065,995	2032-03-26

International Patent Family for US Patent 10,065,995

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012133349
United States of America	2014107315
Japan	WO2012133349
Japan	2017070289